198
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
MINIMIZATION OF COSTS ON MEDICINES USED IN THE TREATMENT OF
STOMACH CANCER
Salokhiddinova, N.T.
Khidoyatova, Z.Sh.
Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan
e-mail: salokhiddinovan@gmail.com
https://doi.org/10.5281/zenodo.17332734
Relevance:
oncological diseases rank second after cardiovascular diseases in terms of
mortality. Stomach cancer is one of the most common oncological diseases. Gastric cancer ranks 5th
in terms of oncological diseases (7%), and 3rd in terms of mortality from cancer (9%). According to
statistics, only 29% of patients recover. Metastases are observed in 80-90% of patients with stomach
cancer, with an early diagnosis of the disease, the 6-month survival rate is 65%, and in the late stages
of the process - less than 15%. The highest survival rate for stomach cancer is in Japan (53%), in
other countries it does not exceed 15-20%. It can develop in any part of the stomach and spread to
other organs, especially the esophagus, lungs, and liver. More than 800,000 people die from this
disease every year in the world. The highest incidence is observed in people over 60 years of age and
in men 2 times more often than in women. Gastric cancer was recorded in them more than 20 times
more often than in people aged 30-39 years.
Purpose of the study:
study of the rational use of drugs used in gastric cancer, analysis of
clinical guidelines and recommendations for gastric cancer, and conducting pharmacoeconomic
research on drugs used in the treatment of the disease.
Materials and methods:
comparative analysis of drugs, clinical observations, cost analysis of
the disease, cost-minimization analysis and reflection, as well as modern statistical analysis.
Retrospective analysis of the "Medical Report of the Patient in the Hospital," the nomenclature of
drugs used for stomach cancer.
Results:
a pharmacoeconomic assessment of the second line of therapy was carried out using
the "cost-effectiveness" method and the "budget impact analysis" method in the treatment of stomach
cancer using the drug Ramutsirumab. Ramutsirumab is considered the only antioangiogenic agent
and is currently registered as an agent used in the treatment of late stages of stomach cancer.
Compared to standard regimens of the second line of gastric cancer chemotherapy, the use of the drug
ramutsirumab is statistically significant and at the same time contributes to an increase in the overall
survival rate to 30%. Ramutsirumab can be characterized as a worthy technology from a clinical and
economic point of view, since the analysis conducted under the "value-effectiveness" scenario
showed that ramutsirumab was comparable in price to or lower than other antitumor drugs containing
monoclonal antibodies included in the list of antiviral drugs. According to the "Budget Effect"
analysis, the provision of ramutsirumab to patients in the late stages of stomach cancer caused budget
savings relative to the provision of oncological patients with bevatsizumab, trastuzumab, and
setuximab drugs used in the treatment of the corresponding nosology.
Conclusions:
according to the results of the conducted research, it can be seen that
ramutsirumab has a good effect on patients when used in a monoregime, and we believe that this drug
can be recommended for the treatment of patients in outpatient settings.
